Executive record

Amnon Peled

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:amnon-peledVersion: public-0As of: 2026-09-29

Not yet claimed6 published Claims1 sources

Key Claims

Biography

PhD with expertise in cytokine research, hematopoietic stem cell biology, inflammation, and cancer. Associate professor at Hadassah Medical Center since 2000, founder and CEO of Biokine Therapeutics, author of over 100 publications and holder of 200+ patents.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2026 to end not publishedExecutive title: Director · Organization not publishedSLXN 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. SLXN 10-K executive officers

    sec filing · Source published: Mar 17, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Silexion Therapeutics Corp · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026
    • Other Company Role: Amnon Peled is also linked to Biokine Therapeutics as Founder and Chief Scientific Officer. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026